PERITONEAL CANCER

This phase 2 study tested a drug called mirvetuximab soravtansine in 79 people with recurrent ovarian, peritoneal, or fallopian tube cancer that had high levels of a protein called folate receptor-alpha. The cancer had come back after platinum-based chemotherapy but was still sen…

This study tested whether the immunotherapy drug pembrolizumab could help keep ovarian cancer from growing after initial chemotherapy. Twenty women with platinum-resistant ovarian, fallopian tube, or peritoneal cancer received weekly paclitaxel followed by pembrolizumab as mainte…

This study followed 388 women with advanced ovarian, fallopian tube, or peritoneal cancer who were taking niraparib as a maintenance treatment to keep their cancer from coming back. Researchers observed how well patients tolerated the drug in everyday clinical practice, without g…

This study looked at 1,500 women with advanced ovarian, peritoneal, or fallopian tube cancer to see how their tumor's genetic makeup relates to their disease. Researchers collected tumor samples and medical data to find links between specific gene changes and how long patients st…

This study tested whether repeated FDG-PET/CT scans can help doctors choose patients and measure treatment response in people with abdominal cancer spread (peritoneal metastasis) receiving a special chemotherapy called PIPAC. 34 patients were enrolled, and the focus was on how we…

This study tested a digital tool (a chatbot) to help cancer survivors learn about genetic testing for hereditary cancer risk. 50 adults who had certain cancers (like breast, ovarian, or prostate) took part. The goal was to see if the chatbot was easy to use and if it helped more …